Companies: 10,795·Total market cap: $144.5T
Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited

TEVANYSEHealthcare● Active
$33.93
$-0.26(-0.76%)
Market Cap$39.5B
P/E Ratio
52W High$37.35
52W Low$14.99

Teva Pharmaceutical Industries Limited (TEVA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

teva · stock forecast · 46 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 46 Wall Street analysts in the past 3 months

SellBuy

Buy

46 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
22
Hold
20
Sell
4
Strong Sell
0
Total: 46 · Buy rate: 47.8%

12-Month Price Target

High

$42.00

Consensus

$39.29

+14.3% upside

Low

$35.00

Median: $40 · Last Close: $34.36

The Teva Pharmaceutical Industries Limited (TEVA) analyst consensus is Buy, based on ratings from 46 Wall Street analysts over the past 3 months. The average 12-month TEVA price target is $39.29, representing +14.3% upside from the current price of $34.36.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $39 (14.3%)

Consensus Target

$39.29

14.3% upside

High Target

$42

22.2%

Low Target

$35

1.9%

Current Price

$34.36

as of today

Based on analyst price targets, the TEVA stock price prediction for the next 12 months ranges from $35 to $42. The consensus TEVA price forecast of $39.29 implies 14.3% upside from the current price of $34.36.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$33.662.04%

1-day model range: $33.49–$33.83. Peak: $33.83 (-2.04%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$53+53.8%
2028$71+107.6%
2029$88+154.8%
2030$101+192.5%
2031+220.6%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

86%7%7%
12Buy
1Neutral
1Sell
RSI (14)52.5Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · TEVA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$33.78BUY
MA 10$34.25BUY
MA 20$34.53SELL
MA 50$33.04BUY
MA 100$32.71BUY
MA 200$28.16BUY
Current $TEVA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$34.14BUY
EMA 10$34.20BUY
EMA 20$34.21BUY
EMA 50$33.46BUY
EMA 100$31.99BUY
EMA 200$28.85BUY
Current $TEVA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Barclays2026-05-06
Maintains
OverweightOverweight
JP Morgan2026-04-30
Maintains
OverweightOverweight
UBS2026-04-30
Maintains
BuyBuy
Piper Sandler2026-04-30
Maintains
OverweightOverweight
Truist Securities2026-04-30
Maintains
BuyBuy
B of A Securities2026-04-09
Maintains
BuyBuy
Piper Sandler2026-03-04
Maintains
OverweightOverweight
Truist Securities2026-02-18
Maintains
BuyBuy
Goldman Sachs2026-02-09
Maintains
BuyBuy
Barclays2026-01-30
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on Teva Pharmaceutical Industries Limited (TEVA) stock. Of the recent 267 rating actions, 62 were upgrades and 54 were downgrades. 46 analysts currently cover TEVA.

Analyst Recommendation Trends

Buy ratings514
Hold ratings00
Sell ratings00

TEVA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 5 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$16.6B

↓ 7.9% YoY

Revenue Next Year

$17.2B

↑ 4.1% YoY

EPS This Year

$2.26

EPS Next Year

$3.10

↑ 37.5% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast TEVA EPS of $2.26 for the current fiscal year, based on estimates from 8 analysts. The TEVA revenue forecast is $16.6B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The TEVA stock forecast is supported by two independent data sources: analyst consensus ratings from 46 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TEVA price target is $39.29 (+14.3% upside), with an analyst consensus of Buy.

The TEVA short-term stock prediction for tomorrow is $33.66 (-2.04%). The TEVA stock price prediction for 2027 estimates an average of $53. The TEVA stock prediction for 2030 projects a range of $95–$106.

Teva Pharmaceutical Industries Limited trades on NYSE under the ticker TEVA. The TEVA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 48% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

TEVA forecast · 8 questions

According to 46 Wall Street analysts, the average 12-month TEVA price target is $39.29, with a high forecast of $42.00 and a low of $35.00. The median price target is shown in the chart above when available. This implies +14.3% potential upside from the current price of $34.36.

TEVA price targetWhat is TEVA price targetTEVA analyst price targetTEVA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.